This trial will study the effectiveness of niraparib, either alone or in combination with other treatments, in women with ovarian, fallopian tube, or primary peritoneal cancer.
3 Primary · 17 Secondary · Reporting Duration: Up to 6 years
Active Control
Experimental Treatment
125 Total Participants · 4 Treatment Groups
Primary Treatment: Niraparib · No Placebo Group · Phase 1 & 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
GSK Investigational Site | 100.0% |
Met criteria | 100.0% |
0 | 100.0% |